Poster: Primary Human Small Intestine Monolayers For Assessing Drug-Induced Intestinal Liabilities In Vitro

Presented at 2023 SOT meeting, collaborators from Janssen Pharmaceuticals describe using  RepliGut® Planar Platform  to distinguish between compounds with different potencies for the JNJ epigenetic target X with a known in vivo GI liability. The poster describes testing a limited set of reference compounds including drugs with a high (> 50%) and a low (0-4%) incidence of diarrhea in the clinic.

Share this article with a friend